AMAL Therapeutics' Series B Round

AMAL Therapeutics raised a round of funding on September 05, 2017.

AMAL Therapeutics is a privately held Swiss biotech start-up company, having spun-out from the University of Geneva. AMAL uses KISIMA, its proprietary vaccine technology platform to develop and progre…

Articles about AMAL Therapeutics' Series B Round: